PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
It is known that currently PARP inhibitors are actively used in the treatment of tumors of the female reproductive system. A large number of studies have been presented demonstrating the effectiveness of PARP inhibitors in the treatment of BRCA-associated ovarian cancer. It was found that mutations...
Saved in:
Main Authors: | D. S. Dolgasheva, A. M. Pevzner, M. K. Ibragimova, N. V. Litvyakov, M. M. Tsyganov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2020-06-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/703 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023
by: M. Ya. Kuzmenko, et al.
Published: (2025-05-01) -
Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
by: K. V. Menshikov, et al.
Published: (2022-06-01) -
PARP9 and PARP14 are involved in microglia-mediated neuroinflammation in Alzheimer′s disease
by: HUANG Lian, WEI Hui
Published: (2025-05-01) -
A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01) -
Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical Implications
by: Martin Kondža, et al.
Published: (2025-05-01)